Myriad Genetics, Inc.

320 Wakara Way
Salt Lake City, UT 84108

USA

Phone: (801) 584-3600
Fax: (801) 584-3640
Email: info@myriad.com
Web Site: http://www.myriad.com/

A. Company Profile

Myriad (NASDAQ:MYGN) is a leader in cancer predisposition testing. The genetic tests provide accuracy, quality, and customer service.

B. Products

Product Pipelines

1. Flurizan

Flurizan (MPC-7869) is the pure R-enantiomer form of flurbiprofen - an NSAID (non-steroidal anti-inflammatory drug) with 25 years of clinical experience behind it. Unlike NSAIDs, however, Flurizan is not an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2). Flurizan modulates the signal transduction and transcription activation pathways associated with nuclear factor kappa B (NFkB), a principle transcription factor in the expression of many molecules involved in cell growth/death and inflammation. Flurizan has demonstrated an excellent safety profile and is very potent in animal models of prostate and colon cancer.

2. BRACAnalysis

BRACAnalysis assesses a woman's risk of developing breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes. The test has become the standard of care in identification of individuals with hereditary breast and ovarian cancer.

3. COLARIS

COLARIS is a predictive medicine test for hereditary colorectal and endometrial cancer. COLARIS detects disease-causing mutations in two genes, MLH1 and MSH2, which are responsible for the majority of hereditary colorectal and endometrial cancers.

4. COLARIS AP

COLARIS AP is a predictive medicine product for risk of hereditary colorectal cancer. COLARIS AP detects mutations in the APC gene, which cause a colon polyp-forming syndrome known as familial adenomatous polyposis (FAP), and a more common variation of the syndrome known as attenuated FAP (AFAP).

5. MELARIS

MELARIS is a predictive medicine test for inherited susceptibility to melanoma and pancreatic cancer. This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), which occur in up to 40% of families with hereditary melanoma. Patient survival is excellent when melanoma is detected at an early stage; however, prognosis is very poor (<15% 5-year survival) when melanoma has spread at the time of diagnosis. Early detection of melanoma is perhaps the best approach to improve outcome.